Poolbeg Pharma PLC Immunomodulator II patent granted in Japan
November 21 2023 - 1:00AM
RNS Non-Regulatory
TIDMPOLB
Poolbeg Pharma PLC
21 November 2023
Poolbeg Pharma plc
Immunomodulator II patent granted in Japan
Further enhancement of the patent portfolio
21 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that
the Japanese Patent Office has notified the Company of its official
decision to grant Poolbeg's Immunomodulator II patent
application.
The claims cover the pharmaceutical composition of POLB 001 for
treating severe influenza in a hospitalised patient in combination
with antiviral compounds, further strengthening the Company's
robust intellectual property in the territory. The formal granted
patent will be received in due course.
In addition, further to the Company's announcement on 20
September 2023 , it has received the fully granted patent for
Immunomodulator I from the Japanese Patent Office.
Poolbeg has a worldwide licence for POLB 001 for all uses in
humans and is developing a strong IP portfolio with patents in
place, including Immunomodulator I and Immunomodulator II, covering
the use of the class of p38 MAP kinase (mitogen-activated protein
kinase) inhibitors for the treatment of severe influenza and the
use of POLB 001 for the treatment of hypercytokinaemia. The Company
continues to seek broader patent protection for POLB 001 and p38
MAP kinase inhibitors in general around the treatment and
prevention of severe influenza and hypercytokinemia, and has also
filed patent applications, to expand its IP around POLB 001, to the
use of p38 MAP kinase inhibitors alongside cancer immunotherapies,
enhancing the value and attractiveness of POLB 001 to potential
pharma partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, commented: "The grant received from the Japanese Patent
Office highlights the progress we are making in developing our
patent portfolio. By strategically growing this exciting molecule's
intellectual property portfolio, we aim to enhance its overall
value for our partners. POLB 001 stands poised to make a
substantial impact on global health and has tremendous potential to
address unmet medical needs worldwide across multiple disease
areas."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team and Board
have been augmented with strong commercialisation expertise
following the appointment of three former members of the Amryt
Pharma plc leadership team, with the intention of repeating Amryt's
success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
across cancer immunotherapies, infectious disease, and an oral
GLP-1 agonist for obesity and other metabolic conditions. It uses a
cost-effective development philosophy to generate high quality
human data to support partnering and further development. Its
AI-led infectious disease programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial
appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABMBRTMTATBMJ
(END) Dow Jones Newswires
November 21, 2023 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From May 2024 to Jun 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2023 to Jun 2024